Clinical Trial Update: Long-term Safety Study of Rapastinel as Adjunctive Therapy in Patients With Major Depressive Disorder [Phase 3]

View source ↗

Summary

Phase 3 long-term safety study of rapastinel as adjunctive therapy in adults with major depressive disorder has completed; results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• Rapastinel (Rapastinel)

Snippet

Sponsor: Naurex, Inc, an affiliate of Allergan plc | Conditions: Depressive Disorder, Major | Phase 3 | Status: COMPLETED | Results posted: 2020-06-22